Pyxis Oncology (PYXS) Price & Analysis

Compare

567 Followers

PYXS Stock Chart & Stats

$1.19

-$0.10(-5.75%)

At close: Jan 08 4:00 PM EST

$1.19

-$0.10(-5.75%)

Day’s Range― - ―

52-Week Range$0.83 - $5.55

Previous CloseN/A

Volume258.73K

Average Volume (3M)757.02K

Market Cap

$79.39M

Enterprise Value$80.22M

Total Cash (Recent Filing)$77.73M

Total Debt (Recent Filing)$19.07M

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Mar 25, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding62,264,214

10 Day Avg. Volume789,983

30 Day Avg. Volume757,017

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.76

Price to Sales (P/S)5.65

P/FCF Ratio-1.57

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue28.45

Enterprise Value/Gross Profit28.45

Enterprise Value/Ebitda-0.98

Forecast

1Y Price Target

$6.90

Price Target Upside479.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyThe combination cohort showed an impressive ORR of 71%, exceeding benchmarks and demonstrating strong efficacy.

Financial PositionThe company reported having approximately $77.7M in cash and equivalents, which is believed to be sufficient to fund operations into the second half of 2026.

Strategic PartnershipsPyxis Oncology has a clinical trial collaboration agreement with Merck for the combination with Keytruda.

Bears Say

Clinical ChallengesConcerns over the tolerability profile given the 28% discontinuation rate, which is higher than the typical 10%-15% acceptable rate in oncology trials.

Financial ChallengesThe company has a limited cash runway of approximately one year, which could pose a financial challenge if additional funding is not secured.

Stock PerformanceThe stock closing down 48.6% for the day.

Pyxis Oncology News

3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three biotech companies that have earned Strong...

3d ago

PYXS

RGNX

Pyxis Oncology price target lowered to $5 from $8 at RBC Capital

RBC Capital analyst Leonid Timashev lowered the firm’s price target on Pyxis Oncology (PYXS) to $5 from $8...

5d ago

PYXS

Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Pyxis Oncology (PYXS) to $7 from $5 and keeps a...

5d ago

PYXS

Pyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotin

Pyxis Oncology (PYXS) announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin, a first-in-concept...

6d ago

MRK

PYXS

Pyxis to present updated data from Phase 1 monotherapy study in mid-2026

In mid-2026, Pyxis Oncology (PYXS) plans to present updated data from the ongoing Phase 1 monotherapy study in...

6d ago

PYXS

Pyxis Oncology sees cash runway into 4Q26

Pyxis Oncology (PYXS) completed sale of its rights to royalties from the commercialization of Enzeshu for a one-time...

6d ago

PYXS

Pyxis Oncology files $350M mixed securities shelf

09:10 EST Pyxis Oncology (PYXS) files $350M mixed securities shelf Published first on TheFly – the ultimate source...

28d ago

PYXS

Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Pyxis Oncology, reducing the price target to...

5d ago

PYXS

Pyxis Oncology Reports Strong MICVO Data and Financing

Pyxis Oncology ( ($PYXS) ) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary...

6d ago

PYXS

Pyxis Oncology price target raised to $8 from $5 at Stephens

Stephens analyst Sudan Loganathan raised the firm’s price target on Pyxis Oncology (PYXS) to $8 from $5 and...

1M ago

PYXS

Pyxis Oncology Reports Increased Losses Amid Development Focus

Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

PYXS

Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints

Pyxis Oncology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

1M ago

PYXS

Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pyxis Oncology and keeping the price target...

1M ago

PYXS

Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday....

2M ago

PYXS

PYXS FAQ

What was Pyxis Oncology’s price range in the past 12 months?

Pyxis Oncology lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.

What is Pyxis Oncology’s market cap?

Pyxis Oncology’s market cap is $79.39M.

When is Pyxis Oncology’s upcoming earnings report date?

Pyxis Oncology’s upcoming earnings report date is Mar 25, 2026 which is in 91 days.

How were Pyxis Oncology’s earnings last quarter?

Pyxis Oncology released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.

Is Pyxis Oncology overvalued?

According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pyxis Oncology pay dividends?

Pyxis Oncology does not currently pay dividends.

What is Pyxis Oncology’s EPS estimate?

Pyxis Oncology’s EPS estimate is -0.33.

How many shares outstanding does Pyxis Oncology have?

Pyxis Oncology has 62,264,214 shares outstanding.

What happened to Pyxis Oncology’s price movement after its last earnings report?

Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.

Which hedge fund is a major shareholder of Pyxis Oncology?

Currently, no hedge funds are holding shares in PYXS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pyxis Oncology Stock Smart Score

Outperform

Fundamentals

Return on Equity

-87.28%

Trailing 12-Months

Asset Growth

-45.93%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pyxis Oncology

Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.

Pyxis Oncology (PYXS) Earnings & Revenues

Historic Earnings Reports

PYXS Stock 12 Month Forecast

Average Price Target

$6.90

▲(479.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,4.7446153846153845,5.099230769230769,5.453846153846154,5.808461538461538,6.163076923076924,6.5176923076923075,6.872307692307692,7.226923076923077,7.581538461538462,7.936153846153847,8.29076923076923,8.645384615384614,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,4.583076923076923,4.7761538461538455,4.969230769230769,5.162307692307692,5.355384615384615,5.548461538461538,5.741538461538461,5.934615384615385,6.127692307692308,6.320769230769231,6.5138461538461545,6.706923076923077,{"y":6.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.39,4.436923076923077,4.483846153846153,4.530769230769231,4.577692307692307,4.624615384615384,4.671538461538462,4.718461538461538,4.765384615384615,4.812307692307693,4.859230769230769,4.906153846153846,4.953076923076923,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >